AV-HALT Screening Technology

ViroStatics has developed proprietary laboratory methodologies to allow our scientists to screen a large number of candidate compounds for their intrinsic anti-HIV activity, unique immunomodulatory properties, impact upon cell cycle progression, and potential toxicities. The Company is interested in reaching out to potential in-licensing partners in the oncology and rheumatology spaces to identify the next generation of AV-HALTs for commercialization to combat HIV/AIDS and other chronic diseases.

Drug Discovery - Drug selection

VS1-002 displays the profile we had established for an AV-HALT with activity equal to VS411 (a combination of hydroxyurea and didanosine) with less mitochondrial toxicity